Food delivery major Swiggy has received approval from its shareholders for a $1.25 billion initial public offering (IPO), according to filings made with the Registrar of Companies sourced by Tofler. The Bengaluru-based firm plans to raise as much as Rs 3,750 crore (around $450 million) via a fresh issue and up to Rs 6,664 crore (around $800 million) through an offer-for-sale (OFS) component, the filings stated.
The combined sales of the branded versions of the products in the US is about $3.5 billion.
Pharmaceutical major Dr Reddy's Laboratories Ltd on Tuesday said it will offer up to 13.5 million American Depositary Shares.
Amidst police security and confusion, classes resumed on Monday at the private school in Bangalore where a three-and-a-half-year-old girl student was sexually abused last week.
Amidst police security and confusion, classes resumed on Monday at the private school in Bangalore where a three-and-a-half-year-old girl student was sexually abused last week.
While Covishield supplies would meet the target of 500 mn doses between August and December, it looks like Covaxin would miss the target of 400 mn unless the partner sites of Bharat Biotech ramp up very rapidly, reports Sohini Das.
Dr Reddy's Laboratories is in a pact with Russian Direct Investment Fund to sell the first 125 million people doses (250 million vials) of Sputnik V in India.
While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.
The first phase of the programme will kick off with vaccinations in Hyderabad on Monday and in Visakhapatnam on Tuesday (May 18) at Apollo facilities.
Lupin will fund the buy through $100 mn cash reserves and a bridge loan.
As per RDIF, Sputnik V has a number of key advantages, including that there are no strong allergies caused by Sputnik V.
The parties intend to start the production of Sputnik V in the beginning of 2021, it added. Currently, Phase III clinical trials are approved and are ongoing in Belarus, the United Arab Emirates, Venezuela and other countries, as well as Phase II-III in India, RDIF said.
Domestic pharma major Panacea Biotec in collaboration with Russian sovereign wealth fund Russian Direct Investment Fund (RDIF) has begun the production of 'Sputnik V' COVID-19 vaccine in India, according to a joint statement issued.
Facebook CEO Mark Zuckerberg recently announced that the company had passed the one-billion user milestone globally, making it the first social network to do so.
The research, which will focus only on plants, has potential to lead to better insights into how stem cells communicate with each other both before and after they are transformed into specialised cells that lead to the development of different plant organs, according to Reddy, principal investigator of the four-year grant.
A US resident has advertised to sell land in that country to Indians here. In the process, the seller may have started a trend of US owners turning to overseas buyers as local demand for housing dries up following the serial bankruptcies from the sub-prime mortgage, or high-risk home loan, crisis.
Offers 12.60% in revenue share to Cidco, while only other bidder GMR offered 10.44%.
Indices reversed all its losses during late trades.
J R D Tata's flight carrying mail between the two cities was the first by an Indian company and it opened the air link to peninsular India.
The government has relaxed the norms for allowing foreign direct investment (FDI) in the construction development sector. It is expected the move will boost affordable housing projects and smart cities across the country.
PSU bank shares were the top gainers on hopes of a rate by the RBI on easing consumer inflation
TCS, ICICI Bank, Sun Pharma,Tata Motors and HDFC among the top losers for the day
The cricketing world is all set for another feast with the Indian Premier League.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances